胺碘酮一直被推荐作为维持心房颤动患者窦性心律的有效药物,其疗效被认为优于其他Ⅰ或Ⅲ类抗心律失常药物。长期给予小剂量胺碘酮已成为房颤治疗的“终极”方案。然而,美国匹兹堡大学Chandhock等新近发表的,对长期胺碘酮治疗进行的研究结果却对此疗法提出了质疑。 Amiodarone has long been recommended as an effective drug for maintaining sinus rhythm in patients with atrial fibrillation and its efficacy is considered superior to other class I or III antiarrhythmic drugs. Chronic administration of low-dose amiodarone has become the “ultimate” cure for AF. However, a recent study by Chandhock, University of Pittsburgh, and others, on long-term amiodarone therapy has challenged the therapy.